Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Benzinga11-26 22:07

On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis. The deal consideration ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486700575?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g4jTRZDi3y.XJAenQDZSdA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/658b5c3c7cbb8a183e1572a7bc98d884","is_english":true,"pubTime":"2024-11-26 22:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486700575","market":"us","top_or_hot":-1,"title":"Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details","media":"Benzinga","content":"<div>\n<p>On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis.\nThe deal consideration ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roches-proposed-acquisition-poseida-therapeutics-140708524.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-26 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roches-proposed-acquisition-poseida-therapeutics-140708524.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis.\nThe deal consideration ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roches-proposed-acquisition-poseida-therapeutics-140708524.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/roches-proposed-acquisition-poseida-therapeutics-140708524.html","article_id":"2486700575","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g4jTRZDi3y.XJAenQDZSdA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/658b5c3c7cbb8a183e1572a7bc98d884"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486700575","pubTimestamp":1732630028,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Tuesday, Roche Holdings AG  agreed to acquire Poseida Therapeutics, Inc.  for an equity value of approximately$1.5 billionon a fully diluted basis.The deal consideration includes $9.00per share in cash plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of$4.00per share in cash upon achievement of specific milestones.Also Read: Roche’s Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings’ $16.5B Catalent Acquisition. The proposed acquisition will establish a new core capability forRoche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.It will include CAR-T programs for solid tumors and autoimmune diseases, Poseida’s genetic engineering platform, and related preclinical medicines.The acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therap","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PSTX":"Poseida Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"罗氏拟收购Poseida Therapeutics有望在癌症和自身免疫性疾病细胞治疗领域建立新的核心能力：详情","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PSTX":1},"content_text":"On Tuesday, Roche Holdings AG (OTC:RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ:PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis.\nThe deal consideration includes $9.00 per share in cash plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones.\nAlso Read: Roche’s Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings’ $16.5B Catalent Acquisition\nThe proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.\nIt will include CAR-T programs for solid tumors and autoimmune diseases, Poseida’s genetic engineering platform, and related preclinical medicines.\nThe acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies.\nIn its third-quarter earnings release, Poseida said it has three programs under Roche collaboration announced in August 2022, including P-BCMA-ALLO1, an allogeneic CAR-T therapy in Phase 1/1b development for multiple myeloma, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T candidate in Phase 1 development for B-cell malignancies. \nIn October, Poseida Therapeutics nominated a new development candidate under its collaboration with Roche. The nomination triggered a $15 million milestone payment from Roche to Poseida.\nThe new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies.\nThe transaction is expected to close in the first quarter of 2025.\nConcurrently, Roche revealed an update on the Phase 3 SKYSCRAPER-01 study of tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC). \nThe 534-patient study did not reach the primary endpoint of overall survival at the final analysis.\nThe overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.\nRoche regularly evaluates its research programs to see if changes are needed to support ongoing studies. The same approach will be applied to this program, with more data from Phase 3 trials in various settings or tumor types expected next year.\nPrice Action: PSTX stock is up 227.3% at $9.36 during the premarket session at last check Tuesday.\nRead Next:\n\nRivian Rides High: $6.6 Billion DOE Loan Commitment Fuels EV Expansion\n\nPhoto via Shutterstock.\nUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.\nGet the latest stock analysis from Benzinga?\n\nPOSEIDA THERAPEUTICS (PSTX): Free Stock Analysis Report\n\nThis article Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486700575"}